Anti-RAGE targets in cachexia: HMGB1, S100B, S100A1
Olga A. Obukhova , Irina N. Mikhailova , Helen M. Treshalina , Irina V. Manina , Irina G. Markina , Ruslan A. Zukov
Clinical nutrition and metabolism ›› 2023, Vol. 4 ›› Issue (2) : 75 -82.
Anti-RAGE targets in cachexia: HMGB1, S100B, S100A1
Cachexia, mediated by the multiligand receptor RAGE (receptor for advanced glycation end products) and its ligands HMGB1, S100B, and S100A1, is a formidable multifactorial complication of the severe course of a number of somatic and malignant diseases. One of the most visualized symptoms of cachexia is a significant decrease in body weight, but the main one is the systemic shutdown of a number of regulatory centers that control the maintenance of homeostasis. Activation of these markers contributes to the launch and intensification of the destructive processes of cachexia, and blocking, in some cases, can reduce their intensity. Among known drugs from various therapeutic groups, there are blockers of one or more markers. For example, Papaverine antispasmodic as well as the nootropic anxiolytic Tenoten, antibacterial Pentamidine and antidepressant Duloxetine. This review describes in detail the significance of the listed markers in the pathogenesis of cachexia, especially in malignant pathology. An assumption was made about the possible control of cachectic progression with the help of such blockers to improve the quality of life of patients.
somatic cachexia / cancer cachexia / pathogenesis / management / RAGE / HMGB1 / S100B / S100A1
Eco-Vector
/
| 〈 |
|
〉 |
PDF
